Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2020-02-28 Regulatory Filings
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Daewon Pharmaceutical regarding its 'Compliance Program' (CP) operations, detailing past performance and future plans. This type of disclosure, which outlines internal governance, ethics, and regulatory compliance programs, does not fit into specific financial reporting categories like 10-K or ER. It is a standard regulatory announcement filed with the exchange (KRX) to inform stakeholders about corporate governance and compliance activities. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous regulatory disclosure.
2020-02-28 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Daewon Pharmaceutical. It outlines the agenda for the upcoming Annual General Meeting, including financial statement approval, dividend proposals, and director appointments. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2020-02-03 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Daewon Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2020-02-03 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Daewon Pharmaceutical Co., Ltd. regarding a 'Decision on Bonus Issue' (무상증자결정). A bonus issue (or stock dividend/capitalization issue) involves the issuance of new shares to existing shareholders, which falls under capital changes. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the appropriate category for announcements regarding new share issues or capital changes.
2020-02-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status and changes in ownership by Fidelity Management & Research Company LLC in Daewon Pharmaceutical Co., Ltd. This type of filing is specifically used to notify the market when a shareholder crosses a significant ownership threshold (typically 5%). According to the provided definitions, this falls under 'Major Shareholding Notification'.
2020-01-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases) made by an executive (Choi Tae-hong) of Daewon Pharmaceutical. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2020-01-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.